慢性乙型肝炎合并糖尿病患者肝纤维化研究进展

摘要/Abstract

摘要： 慢性乙型肝炎(CHB)是全球重要的慢性肝病之一,其长期不良结局主要包括肝纤维化、肝硬化及肝细胞癌等。近年来,糖尿病(DM)在CHB人群中的患病率呈上升趋势,并已被证实为不良肝脏结局的独立危险因素。CHB疾病谱由病毒介导的肝细胞损伤逐步转向以代谢共病驱动为特征的复合疾病状态。本文系统综述了CHB合并DM患者的流行病学特征及肝纤维化进展机制,阐述降糖药物在改善肝纤维化方面的应用前景,强调抗病毒治疗基础上联合代谢综合管理及多学科协作对改善肝纤维化的重要意义,为CHB合并DM患者肝纤维化的综合管理提供参考。

关键词: 慢性乙型肝炎, 糖尿病, 肝纤维化, 病毒-代谢交互作用, 综合管理

张俊, 白雪, 李婕. 慢性乙型肝炎合并糖尿病患者肝纤维化研究进展[J]. 肝脏, 2026, 31(8): 1067-1072.

/ 推荐

参考文献

[1] Seto W K, Lo Y R, Pawlotsky J M, et al. Chronic hepatitis B virus infection[J]. Lancet, 2018, 392(10161): 2313-2324.
[2] Choi W M, Seto W K. Unraveling the metabolic thread: type 2 diabetes and fibrosis in chronic hepatitis B with steatosis[J]. Hepatology, 2026, 83(5): 1046-1048.
[3] Liguori A, Zoncapè M, Casazza G, et al. Staging liver fibrosis and cirrhosis using non-invasive tests in people with chronic hepatitis B to inform WHO 2024 guidelines: a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2025, 10(4): 332-349.
[4] EASL Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2025, 83(2): 502-583.
[5] Li J, Xu L, Rui F, et al. Type 2 diabetes mellitus as an independent predictor of significant fibrosis in treatment-naÏve chronic hepatitis B patients with concurrent hepatic steatosis[J]. Hepatology, 2026, 83(5): 1273-1286.
[6] Luo Y, Li R, Kang J, et al. Chronic hepatitis B with type 2 diabetes mellitus: association between glycemic control and liver fibrosis[J]. World J Diabetes, 2025, 16(7): 107256.
[7] Mederacke I, Filliol A, Affo S, et al. The purinergic P2Y14 receptor links hepatocyte death to hepatic stellate cell activation and fibrogenesis in the liver[J]. Sci Transl Med, 2022, 14(639): eabe5795.
[8] Genitsaridi I, Salpea P, Salim A, et al. 11th edition of the IDF diabetes atlas: global, regional, and national diabetes prevalence estimates for 2024 and projections for 2050[J]. Lancet Diabetes Endocrinol, 2026, 14(2): 149-156.
[9] Lei S, Chen S, Zhao X, et al. Hepatitis B virus infection and diabetes mellitus: the Kailuan prospective cohort study in China[J]. Hepatol Int, 2020, 14(5): 743-753.
[10] Lee J G, Lee S, Kim Y J, et al. Association of chronic viral hepatitis B with insulin resistance[J]. World J Gastroenterol, 2012, 18(42): 6120-6126.
[11] Mavrogiannaki A, Karamanos B, Manesis E K, et al. Prevalence of glucose intolerance in patients with chronic hepatitis B or C: a prospective case-control study[J]. J Viral Hepat, 2009, 16(6): 430-436.
[12] Lee W G, Wells C I, McCall J L, et al. Prevalence of diabetes in liver cirrhosis: a systematic review and meta-analysis[J]. Diabetes Metab Res Rev, 2019, 35(6): e3157.
[13] Jia W, Chan J C, Wong T Y, et al. Diabetes in China: epidemiology, pathophysiology and multi-omics[J]. Nat Metab, 2025, 7(1): 16-34.
[14] Huang S C, Kao J H. The interplay between chronic hepatitis B and diabetes mellitus: a narrative and concise review[J]. Kaohsiung J Med Sci, 2024, 40(1): 6-10.
[15] Mak L Y, Hui R W, Lee C H, et al. Glycemic burden and the risk of adverse hepatic outcomes in patients with chronic hepatitis B with type 2 diabetes[J]. Hepatology, 2023, 77(2): 606-618.
[16] Bo T, Gao L, Yao Z, et al. Hepatic selective insulin resistance at the intersection of insulin signaling and metabolic dysfunction-associated steatotic liver disease[J]. Cell Metab, 2024, 36(5): 947-968.
[17] Hardy T, Oakley F, Anstee Q M, et al. Nonalcoholic fatty liver disease: pathogenesis and disease spectrum[J]. Annu Rev Pathol, 2016, 11: 451-496.
[18] Filali-Mouncef Y, Hunter C, Roccio F, et al. The ménage à trois of autophagy, lipid droplets and liver disease[J]. Autophagy, 2022, 18(1): 50-72.
[19] Du K, Jun J H, Dutta R K, et al. Plasticity, heterogeneity, and multifunctionality of hepatic stellate cells in liver pathophysiology[J]. Hepatol Commun, 2024, 8(5).
[20] Odagiri N, Matsubara T, Sato-Matsubara M, et al. Anti-fibrotic treatments for chronic liver diseases: the present and the future[J]. Clin Mol Hepatol, 2021, 27(3): 413-424.
[21] Parola M, Pinzani M. Liver fibrosis: pathophysiology, pathogenetic targets and clinical issues[J]. Mol Aspects Med, 2019, 65: 37-55.
[22] Lyu C, Kong W, Liu Z, et al. Advanced glycation end-products as mediators of the aberrant crosslinking of extracellular matrix in scarred liver tissue[J]. Nat Biomed Eng, 2023, 7(11): 1437-1454.
[23] Dong H, Zhang Y, Huang Y, et al. Pathophysiology of RAGE in inflammatory diseases[J]. Front Immunol, 2022, 13: 931473.
[24] Lim S G, Baumert T F, Boni C, et al. The scientific basis of combination therapy for chronic hepatitis B functional cure[J]. Nat Rev Gastroenterol Hepatol, 2023, 20(4): 238-253.
[25] Hammerich L, Tacke F. Hepatic inflammatory responses in liver fibrosis[J]. Nat Rev Gastroenterol Hepatol, 2023, 20(10): 633-646.
[26] Sharma S, Le Guillou D, Chen J Y. Cellular stress in the pathogenesis of nonalcoholic steatohepatitis and liver fibrosis[J]. Nat Rev Gastroenterol Hepatol, 2023, 20(10): 662-678.
[27] Witcoski Junior L, de Lima J D, Somensi A G, et al. Metabolic reprogramming of macrophages in the context of type 2 diabetes[J]. Eur J Med Res, 2024, 29(1): 497.
[28] Gray V, Chen W, Tan R J Y, et al. Hyperglycemia-triggered lipid peroxidation destabilizes STAT4 and impairs anti-viral Th1 responses in type 2 diabetes[J]. Cell Metab, 2024, 36(12): 2511-2527.e7.
[29] Cheng J Y, Shan G Y, Wan H, et al. MIF/CD74 axis in hepatic stellate cells mediates HBV-related liver fibrosis[J]. Int Immunopharmacol, 2025, 147: 113929.
[30] Mantovani A, Byrne C D, Targher G. Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review[J]. Lancet Gastroenterol Hepatol, 2022, 7(4): 367-378.
[31] Jin Z, Yin R, Yuan Y, et al. Dapagliflozin ameliorates hepatic steatosis via suppressing LXRα-mediated synthesis of lipids and bile acids[J]. Biochem Pharmacol, 2024, 223: 116167.
[32] Shen Y, Cheng L, Xu M, et al. SGLT2 inhibitor empagliflozin downregulates miRNA-34a-5p and targets GREM2 to inactivate hepatic stellate cells and ameliorate non-alcoholic fatty liver disease-associated fibrosis[J]. Metabolism, 2023, 146: 155657.
[33] Lin J, Huang Y, Xu B, et al. Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial[J]. Bmj, 2025, 389: e083735.
[34] Lee C H, Mak L Y, Tang E H, et al. SGLT2i reduces risk of developing HCC in patients with co-existing type 2 diabetes and hepatitis B infection: a territory-wide cohort study in Hong Kong[J]. Hepatology, 2023, 78(5): 1569-1580.
[35] Yabut J M, Drucker D J. Glucagon-like peptide-1 receptor-based therapeutics for metabolic liver disease[J]. Endocr Rev, 2023, 44(1): 14-32.
[36] Zafer M, Tavaglione F, Romero-Gómez M, et al. Review article: GLP-1 receptor agonists and glucagon/GIP/GLP-1 receptor dual or triple agonists-mechanism of action and emerging therapeutic landscape in MASLD[J]. Aliment Pharmacol Ther, 2025, 61(12): 1872-1888.
[37] Wang M W, Lu L G. Current status of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease: a clinical perspective[J]. J Clin Transl Hepatol, 2025, 13(1): 47-61.
[38] Allam M M, el Gazzar W B. Exendin-4, a glucagon-like peptide-1 receptor agonist downregulates hepatic receptor for advanced glycation end products in non-alcoholic steatohepatitis rat model[J]. Arch Physiol Biochem, 2018, 124(1): 10-17.
[39] Engstr?m A, Wintzell V, Melbye M, et al. Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: a scandinavian cohort study[J]. Hepatology, 2024, 79(6): 1401-1411.
[40] Jara M, Norlin J, Kjær M S, et al. Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis[J]. Nat Med, 2025, 31(9): 3128-3140.
[41] Do A, Zahrawi F, Mehal W Z. Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)[J]. Nat Rev Drug Discov, 2025, 24(3): 171-189.
[42] Akkiz H, Gieseler R K, Canbay A. Liver fibrosis: from basic science towards clinical progress, focusing on the central role of hepatic stellate cells[J]. Int J Mol Sci, 2024, 25(14).
[43] Zhou Z, Jin R, Gu Y, et al. Therapeutic targeting of PPARγ in nonalcoholic fatty liver disease: efficacy, safety, and drug development[J]. Drug Des Devel Ther, 2025, 19: 7293-7319.
[44] Morán-Salvador E, Titos E, Rius B, et al. Cell-specific PPARγ deficiency establishes anti-inflammatory and anti-fibrogenic properties for this nuclear receptor in non-parenchymal liver cells[J]. J Hepatol, 2013, 59(5): 1045-1053.
[45] Tao L, Wu L, Zhang W, et al. Peroxisome proliferator-activated receptor γ inhibits hepatic stellate cell activation regulated by miR-942 in chronic hepatitis B liver fibrosis[J]. Life Sci, 2020, 253: 117572.
[46] Cusi K, Orsak B, Bril F, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial[J]. Ann Intern Med, 2016, 165(5): 305-315.
[47] Petta S, Cammà C, Di Marco V, et al. Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection[J]. Liver Int, 2011, 31(4): 507-515.
[48] EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis-2021 update[J]. J Hepatol, 2021, 75(3): 659-689.
[49] Kim M N, An J, Kim E H, et al. Vibration-controlled transient elastography for significant fibrosis in treatment-naÏve chronic hepatitis B patients: a systematic review and meta-analysis[J]. Clin Mol Hepatol, 2024, 30(Suppl): S106-S116.
[50] 贾婷, 杨晓冬, 高斯媛, 等. 恩替卡韦治疗慢性乙肝并2型糖尿病疗效及肾脏安全性研究[J]. 云南医药, 2024, 45(6): 17-20.
[51] Arita V A, Cabezas M C, Hernández Vargas J A, et al. Effects of Mediterranean diet, exercise, and their combination on body composition and liver outcomes in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of randomized controlled trials[J]. BMC Med, 2025, 23(1): 502.
[52] Hallsworth K, Adams L A. Lifestyle modification in NAFLD/NASH: Facts and figures[J]. JHEP Rep, 2019, 1(6): 468-479.
[53] Cuthbertson D J, Keating S E, Pugh C J A, et al. Exercise improves surrogate measures of liver histological response in metabolic dysfunction-associated steatotic liver disease[J]. Liver Int, 2024, 44(9): 2368-2381.
[54] EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)[J]. J Hepatol, 2024, 81(3): 492-542.